Oral Oncology
Volume 39, Issue 7 , Pages 672-679 , October 2003

Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes

  • Laco Kacani

      Affiliations

    • Department of Otorhinolaryngology, University Hospital Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
    • ,
  • Martin Wurm

      Affiliations

    • Department of Otorhinolaryngology, University Hospital Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
    • ,
  • Harald Schennach

      Affiliations

    • Central Institute for Blood Transfusion, University Hospital Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
    • ,
  • Ilona Braun

      Affiliations

    • Department of Otorhinolaryngology, University Hospital Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
    • ,
  • Jan Andrle

      Affiliations

    • Department of Otorhinolaryngology, University Hospital Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
    • ,
  • Georg M. Sprinzl

      Affiliations

    • Department of Otorhinolaryngology, University Hospital Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43-512-504-5204; fax: +43-512-504-67-5204

Received 28 March 2003 ,Accepted 2 April 2003.

References 

  1. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 2000;36:256–263
  2. Todryk S. A sense of tumour for the immune system. Immunology. 2002;107:1–4
  3. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells (the near future). Int J Cancer. 2001;94:459–473
  4. Urban JL, Holland JM, Kripke ML, Schreiber H. Immunoselection of tumour cell variants by mice suppressed with ultraviolet radiation. J Exp Med. 1982;156:1025–1041
  5. Wortzel RD, Urban JL, Philipps C, Fitch FW, Schreiber H. Independent immunodominant and immunorecessive tumour-specific antigens on a malignant tumour (antigenic dissection with cytolytic T cell clones). J Immunol. 1983;130:2461–2466
  6. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature. 1984;311:750–752
  7. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature. 1985;315:301–305
  8. Restifo NP, Esquivel F, Asher AL, et al.  Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumour immune response. J Immunol. 1999;147:1453–1459
  9. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525–531
  10. Staveley-O’Carroll K, Sotomayor E, Montgomery J, et al.  Induction of antigen-specific T cell anergy: an early event in the course of tumour progression. Proc Natl Acad Sci USA. 1998;95:1178–1183
  11. Ohashi PS, Oehen S, Buerki K, et al.  Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991;65:305–317
  12. Burkly LC, Lo D, Kanagawa O, Brinster RL, Flavell RA. T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I-E. Nature. 1989;342:564–566
  13. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis (an active mode of immune evasion in colon cancer). Br J Cancer. 2001;85:1047–1054
  14. Hahne M, Rimoldi D, Schroter M, et al.  Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumour immune escape. Science. 1996;274:1363–1366
  15. Gorelik L, Flavell RA. Immune-mediated eradication of tumours through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001;7:1118–1122
  16. Kacani L, Frank I, Spruth M, et al.  Dendritic cells transmit human immunodeficiency virus type 1 to monocytes and monocyte-derived macrophages. J Virol. 1998;72:6671–6677
  17. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol. 2001;2:585–589
  18. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer (influence on the immune infiltrate of the cancer). Int J Cancer. 1996;67:333–338
  19. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL. Mechanisms responsible for signaling and functional defects. J Immunother. 1998;21:295–306
  20. Jonuleit H, Kuhn U, Muller G, et al.  Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135–3142
  21. Okamoto M, Hiura K, Ohe G, et al.  Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer. 2000;89:1966–1975
  22. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233–238
  23. Hu HM, Urba WJ, Fox BA. Gene-modified tumour vaccine with therapeutic potential shifts tumour-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol. 1998;161:3033–3041
  24. Knerer B, Hulla W, Martinek H, Formanek M, Temmel A, Kornfehl J. IL-1 and TNF-alpha but no IL-2 expression is found in squamous cell carcinomas of the head and neck by RT-PCR. Acta Otolaryngol. 1996;116:132–136
  25. Sessions DG, Spector GJ, Lenox J, Haughey B, Chao C, Marks J. Analysis of treatment results for oral tongue cancer. Laryngoscope. 2002;112:616–625
  26. Slootweg PJ, Hordijk GJ, Schade Y, van Es RJ, Koole R. Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncol. 2002;38:500–503
  27. O’Brien CJ, Smith JW, Soong SJ, Urist MM, Maddox WA. Neck dissection with and without radiotherapy: prognostic factors, patterns of recurrence, and survival. Am J Surg. 1986;152:456–463
  28. Sprinzl GM, Hussl B, Obrist P, et al.  Dendritic cells in precancerous lesions of the larynx. Laryngoscope. 2000;110:13–18
  29. Ochsenbein AF, Sierro S, Odermatt B, et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 2001;411:1058–1064
  30. Gastman BR, Atarshi Y, Reichert TE, et al.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59:5356–5364

PII: S1368-8375(03)00076-9

doi: 10.1016/S1368-8375(03)00076-9

Oral Oncology
Volume 39, Issue 7 , Pages 672-679 , October 2003

Article Tools

* Image Usage & Resolution